Sarepta Therapeutics, Inc. (SRPT) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.90B USD. 52-week range 14.68 to 24.68 USD. Trailing P/E 46.9. Data as of 2026-10-09.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the ...